DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Virtual Event

2027 年 09 月 07 日 3:00 下午 - 2027 年 09 月 09 日 7:30 下午

(Central European Time)

4051 Basel, Switzerland

Artificial Intelligence in Pharmacovigilance

A practical orientation virtual live training course for the next level of pharmacovigilance technology as it is being implemented across the industry.

Early-Bird rate for DIA Industry Members Available!

DAYS

HOURS

MINUTES

SECONDS

讲师团队

Andrew  Mitchell

Andrew Mitchell

CEO and Founder, YEZA.ai, United States

Andrew is the CEO/Founder of YEZA.ai, delivering AI-Agents for Safety Intake that's transforming Pharmacovigilance. He has consistently led at the forefront of innovation, having successfully delivered two next-gen Safety systems and holds 3 US-patents related to Clinical and PV technology. A 'no nonsense' reputation built on 25 years of experience in software design, development, strategy, implementation, marketing, and go-to-market activities. Extensive experience with Oracle Argus, ArisGlobal LSMV, Veeva Vault Safety and Medidata Rave.

Jan  Petracek, MD, MSc

Jan Petracek, MD, MSc

CEO, iVigee Services a.s., Czech Republic

Jan is a passionate and visionary leader in the field of pharmacovigilance, with over 20 years of experience in the industry. He is the CEO of iVigee, a company that provides innovative and sustainable solutions for drug safety and risk management. He is also a Fellow of the International Society of Pharmacovigilance (FISoP), a Global Fellow in Medicines Development (GFMD), and a Qualified Person for Pharmacovigilance (QPPV). Jan has a proven track record of establishing, growing, and selling successful organizations, both for-profit and non-profit, in the pharmacovigilance sector. He has received multiple awards and recognitions, including the DIA Excellence in Service Award in 2018 and HM Queen's Award for International Trade in 2019.

Representative Invited

Representative Invited

Medicines and Healthcare Products Regulatory Agency (MHRA)

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。